The cancellation of our remaining debt to Perceptive Advisors will reduce our balance sheet debt to zero.
PRINCETON, N.J., March 13, 2024 (Globe Newswire) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's health care company, today announced the announced that it had been repaid. Termination of Debt Facility with Perceptive Advisors (“Perceptive”). This important milestone completes the repayment schedule contemplated in the financing agreement between the Company and Perceptive, which began in 2020 and ended on March 11, 2024. We remain focused on growing Twirla.® and promote the company's business plan.
Al Altomari, Chief Executive Officer and Chairman of Agile, said: “Full debt cancellation with Perceptive is a pivotal moment for our company, and we are excited to continue executing our business plan and growing Twirla. “It shows that we are open to new opportunities.” “We believe this action will provide further balance sheet flexibility as we move forward.”
Mr. Altomari continued, “I would like to thank our partners at Perceptive for working together professionally, cooperatively and constructively to achieve this milestone in a challenging market environment for biotechnology. ” he said.
About Agile Therapeutics
Agile Therapeutics is a women's healthcare company dedicated to meeting the unmet health needs of today's women. Our products and product candidates are designed to provide women with a contraceptive option that frees them from taking daily pills without having to commit to long-acting methods. Our first product, Twirla®, (levonorgestrel and ethinyl estradiol) is a transdermal system and is a non-daily prescribed contraceptive. Twirla is based on our proprietary transdermal patch technology called Skinfusion.®, designed to enable drug delivery through the skin. For more information, please visit the company website: www.agiletherapeutics.com. We may distribute material non-public information on our website and on his LinkedIn account.
positive statement
Certain information contained in this press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, words such as “anticipate”, “believe”, “may”, “continue”, “anticipate”, “estimate”, “anticipate”, “plan”, “intend”, We may use terms such as “may”. To identify these forward-looking statements, words such as “may,” “might,” “likely,” “will,” “should” or future events or results are used to identify these forward-looking statements. Other words that convey uncertainty. The Company's forward-looking statements are based on management's current beliefs and expectations that involve risks, potential changes in circumstances, assumptions and uncertainties and reflect the growth of Twirla, the advancement of its business plans and the Company's It also includes statements regarding our ability to be flexible. Balance sheet. Any or all forward-looking statements may prove to be incorrect or may be subject to inaccurate assumptions made by us or to known and unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties, including risks related to our ability to raise sufficient capital to finance our operations in the short and long term. This includes our ability to raise capital through the issuance of public or private equity securities, debt financing or otherwise. the sources of information, on terms acceptable or at all acceptable to us, our ability to comply with the listing requirements of the Nasdaq Capital Market, and other risks described in our filings with the Securities and Exchange Commission. Form 10-K regarding uncertainties that may cause actual results to differ from those expressed in these forward-looking statements (including a more detailed description of the forward-looking statements) and risks associated with our business generally. See our Annual Report on Form 10-Q and our Quarterly Report on Form 10-Q. . You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any such forward-looking statements to reflect subsequent events or circumstances.
contact:
matt riley
Head of Investor Relations and Corporate Communications
mriley@agiletherapeutics.com
